Chronic kidney disease, lipids and apolipoproteins, and coronary heart disease: the ARIC study

Julio A Lamprea-Montealegre1, A Richey Sharrett2, Kunihiro Matsushita2

  • 1Department of Medicine, University of Maryland School of Medicine, United States.

Atherosclerosis
|March 11, 2014
PubMed

Insights

Chronic kidney disease (CKD) increases coronary heart disease (CHD) risk. While apolipoprotein B to A-1 ratio (ApoB/A1) is higher in CKD, it showed no stronger association with CHD risk than other lipid ratios.

Area of Science:

  • Cardiology
  • Nephrology
  • Lipidology

Background:

  • Chronic kidney disease (CKD) is linked to higher apolipoprotein B to A-1 ratio (ApoB/A1).
  • The comparative association of ApoB/A1 with coronary heart disease (CHD) risk in CKD versus traditional lipid ratios is unclear.

Purpose of the Study:

  • To investigate the association of ApoB/A1 and non-HDL-cholesterol to HDL-cholesterol ratio (NonHDLc/HDLc) with incident CHD in individuals with and without CKD.
  • To compare the strength of association of these markers with CHD risk between CKD and non-CKD populations.

Main Methods:

  • Analysis of 10,137 individuals from the ARIC study, defining CKD by estimated glomerular filtration rate (<60 ml/min/1.73 m²).
  • Utilized Cox proportional hazards regression to assess the association of lipid and apolipoprotein markers with incident CHD.
  • Adjusted for demographic and clinical cardiovascular risk factors.

Main Results:

  • CKD was present in 12% of participants and associated with a higher incidence of CHD events (12.0 vs. 5.2 per 1000 person-years).
  • Individuals with CKD had lower ApoA1 and higher ApoB/A1 compared to those without CKD.
  • Both ApoB/A1 and NonHDLc/HDLc were associated with increased CHD risk in CKD, with no significant difference in strength compared to non-CKD participants.

Conclusions:

  • CKD is associated with dyslipidemia, including lower ApoA1 and higher ApoB/A1.
  • ApoB/A1 is not more strongly associated with CHD incidence in CKD patients than NonHDLc/HDLc.
Abstract

Related Concept Videos

Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
1.8K
Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
2.5K
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
890
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
741
Chronic Kidney Disease II: Clinical Manifestations01:24

Chronic Kidney Disease II: Clinical Manifestations

Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
1.1K
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
1.1K